Campaign India Team
Mar 14, 2022

Piramal Pharma gets Ajay Devgn as its brand ambassador for Tetmosol

Aims to expand its offerings in the skin infection category

Piramal Pharma gets Ajay Devgn as its brand ambassador for Tetmosol

Piramal Pharma’s consumer products division has announced the appointment of actor Ajay Devgn as brand ambassador for its flagship brand, Tetmosol. 

 

With this association, Devgn will be responsible for promoting Testmosol to consumers pan India and aims to enhance its consumer market reach. 

 

The brand aims to expand its offerings in the skin infection category with Tetmosol Dusting Powder and Tetmosol Plus Cream. 

 

Nitish Bajaj, CEO, Piramal Pharma, consumer products division, said, “As we enter the next phase of growth, we are excited to work with Ajay Devgn to promote Tetmosol to our consumers across India and enhance our reach. Owing to the tropical climate, India has a high incidence of skin infections, and therefore we have introduced two new product offerings: Tetmosol Dusting Powder and Tetmosol Plus Cream. Ajay Devgn has established himself as one of India's most popular actors with his fierce performances and resonates very well with our decades-old brand.” 

 

 

Source:
Campaign India

Related Articles

Just Published

2 days ago

Indian singles prioritise compatibility over ...

Only about 11% of women regard financial stability as a critical partner selection criterion, according to a study by Jeevansathi.

2 days ago

Indians among the least satisfied with their love ...

South Korea and Japan are the only two other countries with satisfaction scores lower than that of India, finds Love Life Satisfaction Survey by Ipsos.

2 days ago

50,000 businesses, one goal: Gallabox looks at ...

As traditional channels lose steam, brands are rethinking customer conversations and the SaaS company is helping businesses turn WhatsApp into a sales and marketing powerhouse.

2 days ago

Unilever increases marketing spend by almost $1 billion

The FMCG giant's turnover rose to over $65 billion USD in 2024.